New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

Morten Persson; Palle Damkjær Rasmussen; Jacob Madsen; Michael Ploug; Andreas Kjaer

doi:10.1016/j.nucmedbio.2012.05.007

New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

Morten Persson, Palle Damkjær Rasmussen, Jacob Madsen, Michael Ploug, Andreas Kjaer

Department of Clinical Physiology and Nuclear Medicine

40 Citations (Scopus)

Abstract

The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.

Original language	English
Journal	Nuclear Medicine and Biology
Volume	39
Issue number	7
Pages (from-to)	962-9
Number of pages	8
ISSN	0969-8051
DOIs	https://doi.org/10.1016/j.nucmedbio.2012.05.007
Publication status	Published - 2012

Keywords

Animals
Beta Particles
Cell Transformation, Neoplastic
Colorectal Neoplasms
Dideoxynucleosides
Female
HT29 Cells
Heterocyclic Compounds, 1-Ring
Humans
Lutetium
Mice
Molecular Targeted Therapy
Neoplasm Invasiveness
Oligopeptides
Positron-Emission Tomography
Radioisotopes
Receptors, Urokinase Plasminogen Activator
Substrate Specificity

Access to Document

10.1016/j.nucmedbio.2012.05.007

Cite this

New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. / Persson, Morten; Rasmussen, Palle Damkjær; Madsen, Jacob et al.
In: Nuclear Medicine and Biology, Vol. 39, No. 7, 2012, p. 962-9.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{a878810e398b468eb46b512aa350f3a7,

title = "New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts",

abstract = "The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.",

keywords = "Animals, Beta Particles, Cell Transformation, Neoplastic, Colorectal Neoplasms, Dideoxynucleosides, Female, HT29 Cells, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Mice, Molecular Targeted Therapy, Neoplasm Invasiveness, Oligopeptides, Positron-Emission Tomography, Radioisotopes, Receptors, Urokinase Plasminogen Activator, Substrate Specificity",

author = "Morten Persson and Rasmussen, \{Palle Damkj{\ae}r\} and Jacob Madsen and Michael Ploug and Andreas Kjaer",

year = "2012",

doi = "10.1016/j.nucmedbio.2012.05.007",

language = "English",

volume = "39",

pages = "962--9",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - New peptide receptor radionuclide therapy of invasive cancer cells

T2 - in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

AU - Persson, Morten

AU - Rasmussen, Palle Damkjær

AU - Madsen, Jacob

AU - Ploug, Michael

AU - Kjaer, Andreas

PY - 2012

Y1 - 2012

N2 - The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.

AB - The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.

KW - Animals

KW - Beta Particles

KW - Cell Transformation, Neoplastic

KW - Colorectal Neoplasms

KW - Dideoxynucleosides

KW - Female

KW - HT29 Cells

KW - Heterocyclic Compounds, 1-Ring

KW - Humans

KW - Lutetium

KW - Mice

KW - Molecular Targeted Therapy

KW - Neoplasm Invasiveness

KW - Oligopeptides

KW - Positron-Emission Tomography

KW - Radioisotopes

KW - Receptors, Urokinase Plasminogen Activator

KW - Substrate Specificity

UR - https://www.scopus.com/pages/publications/84866041733

U2 - 10.1016/j.nucmedbio.2012.05.007

DO - 10.1016/j.nucmedbio.2012.05.007

M3 - Journal article

C2 - 22739362

SN - 0969-8051

VL - 39

SP - 962

EP - 969

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

IS - 7

ER -

New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this